Jadelle Levonorgestrel Rod Implants

Jadelle Levonorgestrel Rod Implants PDF Author: Irving Sivin
Publisher: Population
ISBN:
Category : Health & Fitness
Languages : en
Pages : 62

Get Book Here

Book Description

Jadelle Levonorgestrel Rod Implants

Jadelle Levonorgestrel Rod Implants PDF Author: Irving Sivin
Publisher: Population
ISBN:
Category : Health & Fitness
Languages : en
Pages : 62

Get Book Here

Book Description


Jadelle®

Jadelle® PDF Author:
Publisher:
ISBN:
Category : Birth control
Languages : en
Pages :

Get Book Here

Book Description


Jadelle

Jadelle PDF Author: Noel McIntosh
Publisher:
ISBN: 9780929817569
Category :
Languages : en
Pages :

Get Book Here

Book Description


Contraceptive Research, Introduction, and Use

Contraceptive Research, Introduction, and Use PDF Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309174422
Category : Medical
Languages : en
Pages : 128

Get Book Here

Book Description
As the first real contraceptive innovation in over 20 years, and as a long-acting method requiring clinical intervention for application and removal, the implantable contraceptive Norplant has raised a wide range of issues that could offer valuable lessons about the problems to be addressed if other new contraceptive technologies are to enter the marketplace. In April 1997 an Institute of Medicine workshop on implant contraceptives reviewed newly available data on Norplant's efficacy, safety, and use; identified lessons to be learned about the method's development, introduction, use, and market experience; and explored approaches to developing and introducing new contraceptives based on those lessons. This resulting book contains an examination of Norplant's efficacy and safety, its user populations, training for insertion and removal, consumer perspectives (quality of care, informed decisionmaking, and consumer involvement), and new approaches to contraceptive development and introduction. An appendix contains summaries of 17 workshop presentations.

Hormonal Contraception and Post-menopausal Hormonal Therapy

Hormonal Contraception and Post-menopausal Hormonal Therapy PDF Author: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
Publisher: World Health Organization
ISBN:
Category : Medical
Languages : en
Pages : 692

Get Book Here

Book Description
Evaluates evidence for an increased risk of cancer in women using combined oral contraceptives, progestogen-only hormonal contraceptives, post-menopausal estrogen therapy, and post-menopausal estrogen-progestogen therapy. Although the carcinogenicity of these preparations has been extensively investigated, the book stresses the many complex methodological issues that must be considered when interpreting findings and weighing results. Evidence of an association between use of these preparations and positive effects on health, including a reduced risk of some cancers, is also critically assessed. The first and most extensive monograph evaluates evidence of an association between the use of combined oral contraceptives and cancer at nine sites. Concerning breast cancer, the evaluation concludes that, even if the association is causal, the excess risk for breast cancer associated with patterns of use that are typical today is very small. Studies of predominantly high-dose preparations found an increased risk of hepatocellular carcinoma in the absence of hepatitis viruses. Citing these findings, the evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. The evaluation also found sufficient evidence for the carcinogenicity of some, but not all, combined preparations in animals. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. Progestogen-only contraceptives are evaluated in the second monograph, which considers the association with cancer at six sites. The evaluation found no evidence of an increased risk for breast cancer. Although the evaluation found sufficient evidence in animals for the carcinogenicity of medroxyprogesterone acetate, evidence for the carcinogenicity of progestogen-only contraceptives in humans was judged inadequate. Progestogen-only contraceptives were classified as possibly carcinogenic to humans. The third monograph, on post-menopausal estrogen therapy, considers evidence of an association with cancer at eight sites. Findings from a large number of epidemiological studies indicate a small increase in the risk of breast cancer in women who have used these preparations for five years or more. Studies consistently show an association between use of post-menopausal estrogen therapy and an increased risk for endometrial cancer. Data on the association with other cancers were either inconclusive or suggested no effect on risk. The evaluation concludes that post-menopausal estrogen therapy is carcinogenic to humans. The final monograph evaluates the association between the use of post-menopausal estrogen-progestogen therapy and cancer at four sites. The evaluation of limited data on breast cancer found an increased relative risk observed with long-term use. Data were judged insufficient to assess the effects of past use and of different progestogen compounds, doses, and treatment schedules. For endometrial cancer, the evaluation found an increase in risk relative to non-users when the progestogen was added to the cycle for 10 days or fewer. Post-menopausal estrogen-progestogen therapy was classified as possibly carcinogenic to humans. Concerning post-menopausal therapy in general, the book notes that evidence of carcinogenic risks must be placed in perspective of potential benefits. The prevention of osteoporotic fractures is cited as the best-established benefit. Evidence also suggests that estrogen prevents heart disease and may prevent memory loss and dementia.

Selected Practice Recommendations for Contraceptive Use

Selected Practice Recommendations for Contraceptive Use PDF Author: World Health Organization. Reproductive Health and Research
Publisher: World Health Organization
ISBN: 9241562846
Category : Medical
Languages : en
Pages : 144

Get Book Here

Book Description
This document is one of two evidence-based cornerstones of the World Health Organization's (WHO) new initiative to develop and implement evidence-based guidelines for family planning. The first cornerstone, the Medical eligibility criteria for contraceptive use (third edition) published in 2004, provides guidance for who can use contraceptive methods safely. This document, the Selected practice recommendations for contraceptive use (second edition), provides guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate. The recommendations contained in this document are the product of a process that culminated in an expert Working Group meeting held at the World Health Organization, Geneva, 13-16 April 2004.

Fundamentals and Applications of Controlled Release Drug Delivery

Fundamentals and Applications of Controlled Release Drug Delivery PDF Author: Juergen Siepmann
Publisher: Springer Science & Business Media
ISBN: 1461408814
Category : Medical
Languages : en
Pages : 593

Get Book Here

Book Description
This book approaches the subject from a mechanistic perspective that pitches the language at a level that is understandable to those entering the field and who are not familiar with its common phrases or complex terms. It provides a simple encapsulation of concepts and expands on them. In each chapter the basic concept is explained as simply and clearly as possible without a great deal of detail, then in subsequent sections additional material, exceptions to the general rule, examples, etc., is introduced and built up. Such material was generously supplemented with diagrams; conceptually elegant line diagrams in two or three colors. The artwork was well thought out and able to condense the scientific principles into a novel and visually exciting form. The diagrams encourage browsing or draw the reader to salient points. In addition, the technique of highlighting key concepts in a separate box is used throughout each chapter.

Obesity and Gynecology

Obesity and Gynecology PDF Author: Tahir A. Mahmood
Publisher: Elsevier
ISBN: 0128179201
Category : Science
Languages : en
Pages : 353

Get Book Here

Book Description
Obesity and Gynecology, Second Edition, presents updated chapters on a variety of topics, ranging from adolescent obesity, contraception, assisted reproduction and sexual dysfunction, to bariatric surgery and improving semen parameters. The prevalence of obesity in men and women continues to dramatically increase around the world. Obesity presents specific challenges in relation to male and female infertility and general gynecology. Patients who are obese require specific considerations and knowledge. - Presents an essential reference on the significant risks of obesity related to contraception, male and female infertility, and general gynecology - Builds foundational knowledge, showing how obesity relates to general gynecology, including menstrual disorders, breasts cancer, menopause and sexual dysfunction - Assembles critically evaluated chapters that focus on obesity and gynecology to meet the practical needs of gynecologists, endocrinologists and general practitioners

Family Planning

Family Planning PDF Author:
Publisher: JOHNS HOPKINS CCP - INFO
ISBN: 0978856309
Category : Birth control
Languages : en
Pages : 388

Get Book Here

Book Description
"United States Agency for International Development, Bureau for Global Health, Office of Population and Reproductive Health."

Medicines For Women

Medicines For Women PDF Author: Mira Harrison-Woolrych
Publisher: Springer
ISBN: 3319124064
Category : Medical
Languages : en
Pages : 624

Get Book Here

Book Description
In this definitive new text, the major medicines, devices and vaccines used by women worldwide are brought together for the first time in a single volume. Written and edited by international experts with an evidence-based approach, the book offers a comprehensive summary of all the key areas of women’s medicines. In the first part, issues relating to female drug exposure and considerations for prescribing for subgroups of women - for example during pregnancy and lactation - are presented in the context of contemporary clinical practice. In the second part, specific groups of pharmaceutical products are reviewed, including oral contraceptives, emergency contraception, treatment of chronic pelvic pain, hormone replacement therapy, bisphosphonates, herbal medicines for women, contraceptive devices and human papilloma virus (HPV) vaccines. Every chapter reviews and summarises the efficacy and safety of each group of products and concludes with a useful set of clinical take home messages. In the third part, broader perspectives are presented - from a primary care overview of prescribing for women, through to regulatory, political and religious aspects, including issues with women’s medicines in developing countries. The final two chapters focus on risk communication and conclude that women themselves should be placed at the centre of all discussions about their medicines. The book is aimed at prescribers, other healthcare professionals and students in the field of women’s health throughout the world. It is an extremely valuable resource for all in clinical practice, for students of medicine, nursing, pharmacy and related sciences, and also for those in medicines regulation, pharmacovigilance and the pharmaceutical industry.